David Greenberg describes Solenic Medical's non-pharmaceutical solution to implant infections.

Nicole Small describes the investments in infrastructure that are being made to grow entrepreneurs’ ability to keep science at home in DFW.

Elazer Edelman explains how MIT acts as a bridge between the development of technology and the introduction of technology.

Floris Engelhardt describes how Kano is trying to use circular single-stranded DNA to correct gene length stretches of the genome.

Andrey Zarur says that GreenLight is the largest manufacturer of RNA in the wold.

Stella Paffenholz says areas like gene editing, radiopharmaceuticals, and innovative small molecules make this an exciting time.

Imran Eba explains the idea of aiming to treating any disease by stimulating or blocking nerve signals, an investment focus of his firm.

Steve Favaloro explains why the industry is seeing shortages and what is being done by companies to boost supply.

Arjun Goyal describes how firms are trying to navigate both the private and public markets in biotech today.

Bill Maughan discusses Nkarta, ESMO news on Bicycle, BioNTech, Olema, and Xencor, and comments on iPSC companies, Immmunocore, and more.

Dr. Bertozzi describes how types of cell surface glycans play a role in immune modulation and how Palleon is trying to drug them.

Liisa Bayko discusses recent news from Astria Therapeutics, Alnylam, and Akero, and comments on 89bio, Madrigal, Altimmune, and more.

What Truvian's story might say about maturation of the health tech industry today.

Margo Georgiadis describes how Montai is trying to harness anthromolecule chemistry to tackle disease.

Deborah Glasser discusses vaccines for RSV, Covid, E. coli, and more.

Dr. Agarwala gives an intro to the health tech space, describes what areas interest her, and rates the current funding environment.

Victor Bulto discusses the Inflation Reduction Act, radiotherapies, RNA approaches, and health tech.

Dr. Min describes how Cleerly’s technology is designed to improve how CT scans are analyzed.

Dr. Haut talks about demand he is seeing for Leqembi, what it means for the Alzheimer’s field, and opening the blood-brain-barrier.

Salim Syed talks about his recent initiation on CRISPR Therapeutics, and comments on Wave Life Sciences, BridgeBio, Atara, and Cytokinetics.